The Pharmacogenetics to Avoid Loss of Hearing (PALOH) Trial: A Protocol for a Prospective Observational Implementation TrialCitation formats

  • External authors:
  • John Mcdermott
  • Rachel Mahood
  • Ajit Mahaveer
  • Iain Bruce
  • Nicola Booth
  • Rhona Macleod

Standard

The Pharmacogenetics to Avoid Loss of Hearing (PALOH) Trial: A Protocol for a Prospective Observational Implementation Trial. / Newman, William; Mcdermott, John; Mahood, Rachel; Mahaveer, Ajit; Bruce, Iain; Body, Rick; Ulph, Fiona; Booth, Nicola; Macleod, Rhona; Wilson, Paul.

In: BMJ Open, Vol. 11, e044457, 16.06.2021.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Newman, William ; Mcdermott, John ; Mahood, Rachel ; Mahaveer, Ajit ; Bruce, Iain ; Body, Rick ; Ulph, Fiona ; Booth, Nicola ; Macleod, Rhona ; Wilson, Paul. / The Pharmacogenetics to Avoid Loss of Hearing (PALOH) Trial: A Protocol for a Prospective Observational Implementation Trial. In: BMJ Open. 2021 ; Vol. 11.

Bibtex

@article{cd26760e01b44d86809629db265656de,
title = "The Pharmacogenetics to Avoid Loss of Hearing (PALOH) Trial: A Protocol for a Prospective Observational Implementation Trial",
abstract = "Introduction: In conjunction with a beta-lactam, aminoglycosides are the first-choice antibiotic for empirical treatment of sepsis in the neonatal period. The m.1555A>G variant predisposes to ototoxicity after aminoglycoside administration and has a prevalence of 1 in 500. Current genetic testing can take over 24-hours, an unacceptable delay in the acute setting. This prospective-observational trial will implement a rapid point of care test (POCT), facilitating tailored antibiotic prescribing to avoid hearing loss. Methods: The genedriveTM POCT can detect the m.1555A>G variant in 26 minutes from buccal swab. This system will be integrated into the clinical pathways at two large UK neonatal centres over a minimum 6-month period. The primary outcome is the number of neonates successfully tested for the variant out of all babies prescribed antibiotics. As a secondary outcome, clinical timings will be compared to data collected prior to implementation, measuring the impact on routine practice. Ethics and Dissemination: An opt-out consenting process was approved by the Research Ethics Committee (REC) in August 2019. Results will be published in full on completion of the study. Discussion: The m.1555A>G variant is associated with aminoglycoside induced ototoxicity. This was established in 1993, yet technology has not been available to rapidly test for the variant. The genedriveTM assay can detect the variant in a practice-changing timeframe. However, it has not been established whether such a test could be practically implemented. To our knowledge, this trial represents the first example of a genetic POCT being employed in the neonatal setting to alter management acutely. ",
author = "William Newman and John Mcdermott and Rachel Mahood and Ajit Mahaveer and Iain Bruce and Rick Body and Fiona Ulph and Nicola Booth and Rhona Macleod and Paul Wilson",
year = "2021",
month = jun,
day = "16",
doi = "10.1136/bmjopen-2020-044457",
language = "English",
volume = "11",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ ",

}

RIS

TY - JOUR

T1 - The Pharmacogenetics to Avoid Loss of Hearing (PALOH) Trial: A Protocol for a Prospective Observational Implementation Trial

AU - Newman, William

AU - Mcdermott, John

AU - Mahood, Rachel

AU - Mahaveer, Ajit

AU - Bruce, Iain

AU - Body, Rick

AU - Ulph, Fiona

AU - Booth, Nicola

AU - Macleod, Rhona

AU - Wilson, Paul

PY - 2021/6/16

Y1 - 2021/6/16

N2 - Introduction: In conjunction with a beta-lactam, aminoglycosides are the first-choice antibiotic for empirical treatment of sepsis in the neonatal period. The m.1555A>G variant predisposes to ototoxicity after aminoglycoside administration and has a prevalence of 1 in 500. Current genetic testing can take over 24-hours, an unacceptable delay in the acute setting. This prospective-observational trial will implement a rapid point of care test (POCT), facilitating tailored antibiotic prescribing to avoid hearing loss. Methods: The genedriveTM POCT can detect the m.1555A>G variant in 26 minutes from buccal swab. This system will be integrated into the clinical pathways at two large UK neonatal centres over a minimum 6-month period. The primary outcome is the number of neonates successfully tested for the variant out of all babies prescribed antibiotics. As a secondary outcome, clinical timings will be compared to data collected prior to implementation, measuring the impact on routine practice. Ethics and Dissemination: An opt-out consenting process was approved by the Research Ethics Committee (REC) in August 2019. Results will be published in full on completion of the study. Discussion: The m.1555A>G variant is associated with aminoglycoside induced ototoxicity. This was established in 1993, yet technology has not been available to rapidly test for the variant. The genedriveTM assay can detect the variant in a practice-changing timeframe. However, it has not been established whether such a test could be practically implemented. To our knowledge, this trial represents the first example of a genetic POCT being employed in the neonatal setting to alter management acutely.

AB - Introduction: In conjunction with a beta-lactam, aminoglycosides are the first-choice antibiotic for empirical treatment of sepsis in the neonatal period. The m.1555A>G variant predisposes to ototoxicity after aminoglycoside administration and has a prevalence of 1 in 500. Current genetic testing can take over 24-hours, an unacceptable delay in the acute setting. This prospective-observational trial will implement a rapid point of care test (POCT), facilitating tailored antibiotic prescribing to avoid hearing loss. Methods: The genedriveTM POCT can detect the m.1555A>G variant in 26 minutes from buccal swab. This system will be integrated into the clinical pathways at two large UK neonatal centres over a minimum 6-month period. The primary outcome is the number of neonates successfully tested for the variant out of all babies prescribed antibiotics. As a secondary outcome, clinical timings will be compared to data collected prior to implementation, measuring the impact on routine practice. Ethics and Dissemination: An opt-out consenting process was approved by the Research Ethics Committee (REC) in August 2019. Results will be published in full on completion of the study. Discussion: The m.1555A>G variant is associated with aminoglycoside induced ototoxicity. This was established in 1993, yet technology has not been available to rapidly test for the variant. The genedriveTM assay can detect the variant in a practice-changing timeframe. However, it has not been established whether such a test could be practically implemented. To our knowledge, this trial represents the first example of a genetic POCT being employed in the neonatal setting to alter management acutely.

U2 - 10.1136/bmjopen-2020-044457

DO - 10.1136/bmjopen-2020-044457

M3 - Article

VL - 11

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

M1 - e044457

ER -